2025
SJR Q1
JCR Q2 · 3,3
38 eşleşen makale
SCIE
Dergi ayrıntısı
Psychopharmacology
- Yayıncı
- Springer Science and Business Media Deutschland GmbH
- Ülke
- Germany · Western Europe
- Tür
- journal
- ISSN
-
0033315814322072
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,147
- Quartile Q1
- H-Index 224
- Atıf/yayın 3,38
- Doküman (3y) 652
- Atıf (3y) 2.548
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,3
- 5Y JIF 3,5
- JCI 0,89
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Pharmacology Q1
Alanlar
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Neurosciences | Pharmacology & Pharmacy | Psychiatry
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 1,147 | 3,3 | 3,5 | 0,89 | Q2 | 224 |
| 2024 | Q1 | Q2 | 1,157 | 3,3 | 3,3 | 0,94 | Q2 | 218 |
| 2023 | Q1 | Q2 | 1,053 | 3,5 | 3,6 | 0,92 | Q2 | 218 |
| 2022 | Q1 | Q2 | 1,05 | 3,4 | 3,7 | 0,91 | Q2 | 218 |
| 2021 | Q1 | Q2 | 1,103 | 4,4 | 4,3 | 0,98 | Q2 | 218 |
| 2020 | Q1 | Q2 | 1,378 | 4,5 | 4,1 | 1,07 | Q1 | 218 |
| 2019 | Q1 | Q2 | 1,253 | 3,1 | 3,2 | 1,07 | Q1 | 218 |
| 2018 | — | Q2 | — | 3,4 | 3,3 | 1,1 | Q1 | — |
| 2017 | Q1 | Q2 | 1,494 | 3,2 | 3,3 | 1,1 | Q1 | 218 |
| 2016 | Q1 | Q2 | 1,714 | 3,3 | 3,5 | — | — | 218 |
| 2015 | Q1 | Q1 | 1,721 | 3,5 | 3,8 | — | — | 218 |
| 2014 | Q1 | Q1 | 1,955 | 3,9 | 4 | — | — | 218 |
| 2013 | Q1 | Q1 | 2,121 | 4 | 4,1 | — | — | 218 |
| 2012 | Q1 | Q1 | 2,038 | 4,1 | 4,3 | — | — | 218 |
| 2011 | Q1 | Q1 | 1,994 | 4,1 | 4,4 | — | — | 218 |
| 2010 | Q1 | Q1 | 2,125 | 3,8 | 4,1 | — | — | 218 |
| 2009 | — | Q1 | — | 4,1 | 4,3 | — | — | — |
| 2008 | — | Q1 | — | 3,7 | 4,2 | — | — | — |
| 2007 | — | Q1 | — | 3,6 | 4 | — | — | — |
| 2006 | — | Q1 | — | 3,6 | — | — | — | — |
| 2005 | — | Q1 | — | 4 | — | — | — | — |
| 2004 | — | Q1 | — | 3,1 | — | — | — | — |
| 2003 | — | Q1 | — | 3,4 | — | — | — | — |
| 2002 | — | Q1 | — | 3,3 | — | — | — | — |
| 2001 | — | Q1 | — | 3,1 | — | — | — | — |
| 2000 | — | Q1 | — | 2,8 | — | — | — | — |
| 1999 | — | Q1 | — | 2,9 | — | — | — | — |
| 1998 | — | Q1 | — | 3 | — | — | — | — |
| 1997 | — | Q1 | — | 2,9 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | NEUROSCIENCES | SCIE | Q2 | Q2 | 156/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 149/356 |
| 2025 | PSYCHIATRY | SCIE | Q2 | Q2 | 97/293 |
| 2024 | NEUROSCIENCES | SCIE | Q2 | Q2 | 122/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 122/352 |
| 2024 | PSYCHIATRY | SCIE | Q2 | Q2 | 86/288 |
| 2023 | NEUROSCIENCES | SCIE | Q2 | Q2 | 110/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 100/354 |
| 2023 | PSYCHIATRY | SCIE | Q2 | Q2 | 75/279 |
| 2022 | NEUROSCIENCES | SCIE | Q2 | Q2 | 136/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 125/278 |
| 2022 | PSYCHIATRY | SCIE | Q3 | Q2 | 82/155 |
| 2021 | NEUROSCIENCES | SCIE | Q2 | Q2 | 109/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 98/279 |
| 2021 | PSYCHIATRY | SCIE | Q2 | Q2 | 71/155 |
| 2020 | NEUROSCIENCES | SCIE | Q2 | Q2 | 91/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 81/276 |
| 2020 | PSYCHIATRY | SCIE | Q2 | Q1 | 47/156 |
| 2019 | NEUROSCIENCES | SCIE | Q2 | Q2 | 124/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 101/271 |
| 2019 | PSYCHIATRY | SCIE | Q2 | Q1 | 56/155 |
| 2018 | NEUROSCIENCES | SCIE | Q2 | Q2 | 103/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 77/267 |
| 2018 | PSYCHIATRY | SCIE | Q2 | Q1 | 49/146 |
| 2017 | NEUROSCIENCES | SCIE | Q2 | Q2 | 112/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 79/261 |
| 2017 | PSYCHIATRY | SCIE | Q2 | Q1 | 48/142 |
| 2016 | NEUROSCIENCES | SCIE | Q2 | — | 97/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 68/257 |
| 2016 | PSYCHIATRY | SCIE | Q2 | — | 47/142 |
| 2015 | NEUROSCIENCES | SCIE | Q2 | — | 82/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 61/255 |
| 2015 | PSYCHIATRY | SCIE | Q2 | — | 38/142 |
| 2014 | NEUROSCIENCES | SCIE | Q2 | — | 73/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 47/255 |
| 2014 | PSYCHIATRY | SCIE | Q1 | — | 33/140 |
| 2013 | NEUROSCIENCES | SCIE | Q2 | — | 75/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 37/256 |
| 2013 | PSYCHIATRY | SCIE | Q1 | — | 30/136 |
| 2012 | NEUROSCIENCES | SCIE | Q2 | — | 67/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 42/261 |
| 2012 | PSYCHIATRY | SCIE | Q1 | — | 28/135 |
| 2011 | NEUROSCIENCES | SCIE | Q1 | — | 58/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 43/261 |
| 2011 | PSYCHIATRY | SCIE | Q1 | — | 26/130 |
| 2010 | NEUROSCIENCES | SCIE | Q2 | — | 71/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 47/252 |
| 2010 | PSYCHIATRY | SCIE | Q1 | — | 27/128 |
| 2009 | NEUROSCIENCES | SCIE | Q1 | — | 54/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 36/237 |
| 2009 | PSYCHIATRY | SCIE | Q1 | — | 22/117 |
| 2008 | NEUROSCIENCES | SCIE | Q2 | — | 62/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 46/219 |
| 2008 | PSYCHIATRY | SCIE | Q2 | — | 28/101 |
| 2007 | NEUROSCIENCES | SCIE | Q2 | — | 63/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 45/205 |
| 2007 | PSYCHIATRY | SCIE | Q2 | — | 26/94 |
| 2006 | NEUROSCIENCES | SCIE | Q2 | — | 55/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 43/199 |
| 2006 | PSYCHIATRY | SCIE | Q2 | — | 24/94 |
| 2005 | NEUROSCIENCES | SCIE | Q1 | — | 45/200 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 28/193 |
| 2005 | PSYCHIATRY | SCIE | Q1 | — | 14/94 |
| 2004 | NEUROSCIENCES | SCIE | Q2 | — | 59/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 42/187 |
| 2004 | PSYCHIATRY | SCIE | Q1 | — | 18/90 |
| 2003 | NEUROSCIENCES | SCIE | Q1 | — | 49/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 34/185 |
| 2003 | PSYCHIATRY | SCIE | Q1 | — | 18/87 |
| 2002 | NEUROSCIENCES | SCIE | Q1 | — | 49/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 32/188 |
| 2002 | PSYCHIATRY | SCIE | Q1 | — | 12/88 |
| 2001 | NEUROSCIENCES | SCIE | Q2 | — | 52/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 28/186 |
| 2001 | PSYCHIATRY | SCIE | Q1 | — | 14/81 |
| 2000 | NEUROSCIENCES | SCIE | Q2 | — | 54/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 30/181 |
| 2000 | PSYCHIATRY | SCIE | Q1 | — | 16/82 |
| 1999 | NEUROSCIENCES | SCIE | Q1 | — | 50/201 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 23/175 |
| 1999 | PSYCHIATRY | SCIE | Q1 | — | 14/80 |
| 1998 | NEUROSCIENCES | SCIE | Q1 | — | 40/202 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 20/178 |
| 1998 | PSYCHIATRY | SCIE | Q1 | — | 13/77 |
| 1997 | NEUROSCIENCES | SCIE | Q2 | — | 40/150 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 21/157 |
| 1997 | PSYCHIATRY | SCIE | Q1 | — | 12/67 |